Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 234 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 234 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $10,983.96. Following the transaction, the insider now owns 78,393 shares of the company’s stock, valued at approximately $3,679,767.42. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37.
• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $6,048.00.

Twist Bioscience Price Performance

TWST traded up $1.17 during midday trading on Tuesday, hitting $46.46. 407,885 shares of the company’s stock traded hands, compared to its average volume of 1,002,683. The company has a market cap of $2.71 billion, a PE ratio of -13.48 and a beta of 1.76. The stock’s fifty day simple moving average is $47.05 and its 200-day simple moving average is $43.14. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. Twist Bioscience’s revenue was up 27.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.01) EPS. On average, research analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TWST shares. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. The Goldman Sachs Group raised their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Barclays decreased their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of the company. American International Group Inc. raised its position in shares of Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares during the period. Caprock Group LLC grew its stake in shares of Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after acquiring an additional 220 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after acquiring an additional 308 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after acquiring an additional 312 shares during the last quarter. Finally, CWM LLC grew its stake in shares of Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after acquiring an additional 524 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.